First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials

Bortezomib-melphalan-prednisone (VMP) and continuous lenalidomide-dexamethasone (Rd) represent the standard treatment of transplant-ineligible patients with newly diagnosed multiple myeloma (MM). To date, no randomized trial has compared VMP to Rd, and there is no evidence of the optimal treatment f...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Haematologica
Main Authors: Larocca, Alessandra, Mina, Roberto, Offidani, Massimo, Liberati, Anna Marina, Ledda, Antonio, Patriarca, Francesca, Evangelista, Andrea, Spada, Stefano, Benevolo, Giulia, Oddolo, Daniela, Innao, Vanessa, Cangiolosi, Clotilde, Bernardini, Annalisa, Musto, Pellegrino, Amico, Valeria, Fraticelli, Vincenzo, Paris, Laura, Giuliani, Nicola, Falcone, Antonietta Pia, Zambello, Renato, De Paoli, Lorenzo, Romano, Alessandra, Palumbo, Antonio, Montefusco, Vittorio, Hájek, Roman, Boccadoro, Mario, Bringhen, Sara
Format: Artigo
Sprog:Inglês
Udgivet: Ferrata Storti Foundation 2020
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7109734/
https://ncbi.nlm.nih.gov/pubmed/31248973
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2019.220657
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker